Reinstatement of dapsone following hypersensitivity.
Labandeira
Javier
J
Toribio
Jaime
J
D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects*; D003874:Dermatitis Herpetiformis / Q000188:drug therapy*; D003937:Diagnosis, Differential; D004032:Diet; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D005121:Extremities; D005148:Facial Dermatoses / Q000139:chemically induced / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006801:Humans
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003622:Dapsone